Advancis launches Keflex 750 mg capsules oral antibiotic

By E. Janene Geiss

Philadelphia, July 25 - Advancis Pharmaceutical Corp. announced Tuesday the commercial launch of Keflex 750 mg capsules.

The new strength of Keflex allows health care professionals the flexibility to deliver higher doses of Keflex with fewer capsules per day, according to a company news release.

Keflex 750 mg capsules have been manufactured, packaged and are being distributed to pharmacies nationwide in bottles of 50 capsules, officials said.

The company's sales force will begin promoting Keflex 750 mg capsules to high volume prescribers across the United States, officials said. Advancis has deployed 83 field-based sales personnel, including 75 sales representatives and eight district sales managers, fully dedicated to the promotion of Keflex 750 mg.

Sales representatives from Advancis have been presenting Keflex 750 mg to pharmacists and pharmaceutical distributors since July 17.

Sales representatives are expected to begin directly promoting Keflex 750 mg to targeted physicians as well as providing patient starter samples later this week.

The company said it expects to see measurable Keflex 750 mg prescription volume beginning the week of July 31.

Advancis acquired the rights to manufacture, market and sell Keflex in the United States in July 2004.

Cephalexin is the third most prescribed outpatient antibiotic in the United States with more than 25 million prescriptions written annually.

Keflex is the No. 1 most prescribed oral cephalosporin antibiotic and is also the No. 1 recommended oral antibiotic therapy for uncomplicated skin and skin structure infections, officials said.

Advancis received approval for introduction of the Keflex 750 mg capsules in May.

Advancis is a Germantown, Md., pharmaceutical company focused on pulsatile drug products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.